全文获取类型
收费全文 | 290981篇 |
免费 | 27652篇 |
国内免费 | 22343篇 |
专业分类
耳鼻咽喉 | 2251篇 |
儿科学 | 2725篇 |
妇产科学 | 3324篇 |
基础医学 | 35453篇 |
口腔科学 | 4867篇 |
临床医学 | 41495篇 |
内科学 | 42510篇 |
皮肤病学 | 2649篇 |
神经病学 | 15867篇 |
特种医学 | 10501篇 |
外国民族医学 | 208篇 |
外科学 | 28022篇 |
综合类 | 49207篇 |
现状与发展 | 79篇 |
一般理论 | 29篇 |
预防医学 | 17962篇 |
眼科学 | 9007篇 |
药学 | 31447篇 |
318篇 | |
中国医学 | 17386篇 |
肿瘤学 | 25669篇 |
出版年
2024年 | 1056篇 |
2023年 | 4786篇 |
2022年 | 12413篇 |
2021年 | 15398篇 |
2020年 | 11738篇 |
2019年 | 10124篇 |
2018年 | 10569篇 |
2017年 | 9479篇 |
2016年 | 8946篇 |
2015年 | 13456篇 |
2014年 | 16590篇 |
2013年 | 14105篇 |
2012年 | 20910篇 |
2011年 | 23864篇 |
2010年 | 14696篇 |
2009年 | 11453篇 |
2008年 | 14995篇 |
2007年 | 14937篇 |
2006年 | 15108篇 |
2005年 | 15056篇 |
2004年 | 9161篇 |
2003年 | 8416篇 |
2002年 | 7071篇 |
2001年 | 6298篇 |
2000年 | 6997篇 |
1999年 | 7734篇 |
1998年 | 5102篇 |
1997年 | 5087篇 |
1996年 | 3982篇 |
1995年 | 3798篇 |
1994年 | 3158篇 |
1993年 | 2115篇 |
1992年 | 2393篇 |
1991年 | 1980篇 |
1990年 | 1677篇 |
1989年 | 1420篇 |
1988年 | 1239篇 |
1987年 | 1090篇 |
1986年 | 834篇 |
1985年 | 670篇 |
1984年 | 373篇 |
1983年 | 236篇 |
1982年 | 124篇 |
1981年 | 140篇 |
1980年 | 89篇 |
1979年 | 100篇 |
1978年 | 2篇 |
1963年 | 1篇 |
1962年 | 2篇 |
1961年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
41.
42.
43.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
44.
Anatoly E Martynyuk Ling-Sha Ju Timothy E Morey Jia-Qiang Zhang 《World Journal of Psychiatry》2020,10(5):81-94
The progress of modern medicine would be impossible without the use of general anesthetics (GAs). Despite advancements in refining anesthesia approaches, the effects of GAs are not fully reversible upon GA withdrawal. Neurocognitive deficiencies attributed to GA exposure may persist in neonates or endure for weeks to years in the elderly. Human studies on the mechanisms of the long-term adverse effects of GAs are needed to improve the safety of general anesthesia but they are hampered not only by ethical limitations specific to human research, but also by a lack of specific biological markers that can be used in human studies to safely and objectively study such effects. The latter can primarily be attributed to an insufficient understanding of the full range of the biological effects induced by GAs and the molecular mechanisms mediating such effects even in rodents, which are far more extensively studied than any other species. Our most recent experimental findings in rodents suggest that GAs may adversely affect many more people than is currently anticipated. Specifically, we have shown that anesthesia with the commonly used GA sevoflurane induces in exposed animals not only neuroendocrine abnormalities (somatic effects), but also epigenetic reprogramming of germ cells (germ cell effects). The latter may pass the neurobehavioral effects of parental sevoflurane exposure to the offspring, who may be affected even at levels of anesthesia that are not harmful to the exposed parents. The large number of patients who require general anesthesia, the even larger number of their future unexposed offspring whose health may be affected, and a growing number of neurodevelopmental disorders of unknown etiology underscore the translational importance of investigating the intergenerational effects of GAs. In this mini review, we discuss emerging experimental findings on neuroendocrine, epigenetic, and intergenerational effects of GAs. 相似文献
45.
46.
47.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
48.
49.
50.
【目的】探讨中药淫羊藿、巴戟天提取物(中药注射液喘可治的组成)对恒河猴单核衍生的巨噬细胞在未极化(M0)、M1极化条件下基因表达的影响,分析其可能的免疫调节的作用机制。【方法】采用密度梯度离心法分离中国恒河猴外周血单个核细胞(PBMCs),采用贴壁法纯化出单核细胞,并以粒细胞巨噬细胞集落刺激因子(GM-CSF)刺激5 d以使单核细胞分化成巨噬细胞;然后不加入极化因子(M0)或以干扰素γ(IFN-γ,继续培养2 d)诱导巨噬细胞极化为M1表型,同时分别加入淫羊藿、巴戟天提取物进行干预;然后提取m RNA并逆转录后,采用实时荧光定量PCR检测CCR5、CD4、CTLA-4、Fox P3、IDO、IL-10、TGF-β等基因表达量。【结果】与空白对照组比较,加入巴戟天提取物培养的M0巨噬细胞基因表达上调不明显;经淫羊藿提取物培养的M0巨噬细胞,CCR5基因表达量上调4.21倍,TGF-β上调7.66倍,Fox P3、IL-10轻度上调,而CD4、CTLA-4、IDO等基因表达改变倍数无明显变化。经巴戟天提取物刺激的M1型巨噬细胞,CTLA-4基因表达量上调3.22倍,Fox P3上调3.69倍,CCR5、CD4、IL-10、IDO基因改变倍数均无明显变化,TGF-β未测出;而由淫羊藿提取物刺激的M1型巨噬细胞,IL-10的表达量上调11.83倍,Fox P3上调4.55倍,IDO、CCR5、CD4、CTLA-4基因改变倍数无明显变化,TGF-β未测出。【结论】巴戟天和淫羊藿提取物培养能够上调M1型巨噬细胞IL-10、Fox P3、CTLA-4等抑炎基因表达,淫羊藿提取物能够上调M0巨噬细胞CCR5和TGF-β等基因表达,促进病原体清除和组织修复,从而发挥多效免疫调节作用。 相似文献